Vanberra Signal
Free trial

Depixus

Curated by Signal

Provider of solutions for single-molecule genetic and epigenetic sequencing

Health Technologydepixus.com

Overview

Provider of solutions for single-molecule genetic and epigenetic sequencing. The platform technology SIMDEQ (SIngle-molecule Magnetic Detection and Quantification), initially developed at École Normale Supérieure (ENS), exploits the biophysical properties of DNA and RNA to enable genetic and epigenetic sequencing. The DNA and RNA are converted into a 'hairpin' library that is immobilized on a magnetic bead. Under the influence of a magnetic field, these hairpins are 'zipped' and 'unzipped'.

Key facts

Founded
2012
Headquarters
Paris, France
Stage
Sign up to view
Industry
Health Technology

Business model

1 product or service
Sign up to view

Contact

Primary office
Sign up to view
Email
Sign up to view
Phone
Sign up to view

More on Vanberra Signal

Members only
Business overviewCore metrics and financialsPeopleLeadership and key peopleSimilar companiesPeers and competitorsDeep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

  • Peppy

    Online platform offering video-based training sessions for individuals

    Health TechnologyLa Rochelle, France

  • MesVaccins.net

    Mobile-based application for vaccination health record management

    Health TechnologyBordeaux, France

  • Dentapoche

    Digital teleconsultation platform for providers and patients

    Health TechnologyPau, France

About Depixus

What does Depixus do?

Provider of solutions for single-molecule genetic and epigenetic sequencing.

Where is Depixus headquartered?

Depixus is headquartered in Paris, France.

When was Depixus founded?

Depixus was founded in 2012.

Which sector is Depixus in?

Depixus operates in Health Technology.

Who are Depixus's competitors?

Companies similar to Depixus include Peppy, MesVaccins.net, and Dentapoche.